MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first described by researchers in 2015, and the research on it comes from rodent and laboratory studies.2 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no product containing it authorized in the European Union.2 FDA found no clinical studies or other human exposure data for MOTS-c, so its effects and safety in people are unknown.2 FDA staff recommended against adding MOTS-c to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.2,5,6
MOTS-c at a glance
What it is
A naturally occurring 16-amino-acid peptide encoded in mitochondrial DNA. FDA’s evaluation covers synthetic free-base and acetate forms.2
FDA status
Not FDA-approved. FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, MOTS-c acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.2,5,6
Human evidence
None found by FDA for MOTS-c itself. HHS’s policy document cites a placebo-controlled trial of a related analogue.2,6
Sport status
FDA’s briefing notes that MOTS-c appears as a prohibited substance in the Global Drug Reference Online database, which draws on the World Anti-Doping Agency’s 2024 prohibited list, as FDA checked in March 2024.2
Evidence strength
Animal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned
What is MOTS-c?
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c. It is a peptide of 16 amino acids that cells make from a short stretch of mitochondrial DNA, and it circulates naturally in the blood of humans and rodents.2
Researchers first described MOTS-c in 2015. FDA could not determine how long it has been used in pharmacy compounding, and outsourcing facilities reported no products containing it from 2017 to December 2025.2
FDA found MOTS-c marketed online, alone and in combination with other substances, for uses including metabolism, weight loss, physical performance and slowing cellular aging.2
How is MOTS-c thought to work?
In rodent studies, MOTS-c affected glucose and fat metabolism, bone remodeling and blood vessels, apparently through a cellular energy-sensing pathway known as AMPK.2
FDA cautions that these findings come only from rodent models, that the studies did not test whether larger amounts produced larger effects, and that MOTS-c’s molecular targets remain unknown, which makes it hard to predict which organs it would affect.2
A laboratory study found that MOTS-c is broken down quickly in human blood, which FDA says raises the question of whether giving it from outside the body can reach active levels.2
What do human studies show?
FDA’s review found none. FDA did not identify any clinical study evaluating MOTS-c in people, and the twelve references submitted to FDA in support of MOTS-c included no clinical studies.2
FDA found no pharmacokinetic data in people, and its searches of FDA’s adverse-event database through March 2025 found no reports.2
HHS’s policy document cites a randomized, placebo-controlled trial of a MOTS-c analogue that it says reported no serious adverse events. That trial tested a related compound, not MOTS-c itself, and the policy document does not identify it further.6
FDA concluded that there is a lack of evidence to evaluate whether MOTS-c works for the proposed uses and that its safety risks in people are unknown.2
What the evidence base contains
Animal or laboratory research Mouse and rat studies reporting less diet-induced weight gain, better insulin sensitivity, effects on bone, and less blood-vessel calcification. FDA notes that the studies did not test whether larger amounts produced larger effects.2
Animal or laboratory research A laboratory study reporting that MOTS-c is broken down quickly in human blood.2
No. FDA’s May 2026 evaluation states that neither MOTS-c free base nor MOTS-c acetate is a component of an FDA-approved drug and that there is no United States Pharmacopeia monograph for either.2
Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5
FDA staff evaluated both forms of MOTS-c for that list and recommended against adding either. They cited poor chemical characterization, unknown extent of use, no nonclinical toxicity data, and no clinical studies of safety or effectiveness. FDA’s meeting page lists obesity and osteoporosis as the uses FDA reviewed, and FDA notes that approved treatments exist for both.2,3
HHS’s policy document states that MOTS-c was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.1,6
FDA’s Pharmacy Compounding Advisory Committee discussed MOTS-c on July 23, 2026. HHS’s policy document states that the committee voted in favor of both forms, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.2,3,6
On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6
Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For MOTS-c, the policy covers only the acetate salt form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6
HHS and FDA staff weigh the same record differently. HHS’s policy document says newer certificates from FDA-registered manufacturers supply the quality test results FDA staff found missing, that use is now documented, and that the available safety evidence, including the analogue trial and rodent studies, points in one direction. FDA staff had found no human data on MOTS-c at all.2,6
The policy does not make MOTS-c an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6
Timeline
Researchers first describe MOTS-c, according to the literature FDA reviewed.2
MOTS-c is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.6
A Federal Register notice announces the July advisory-committee meeting that will discuss MOTS-c and opens a public comment docket.4
MOTS-c leaves Category 2, according to HHS’s policy document.6
FDA staff date their evaluation recommending that MOTS-c not be added to the 503A bulks list.2
HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists MOTS-c among six peptide substances used in compounding.5,6
What is still unknown?
Whether MOTS-c has any benefit in people: FDA found no clinical studies of it for any condition.2
Its safety in people, whether it can trigger immune reactions, and whether it stays in the blood long enough to act.2
What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that inconsistent naming is a safety risk.2
Whether FDA’s rulemaking will add MOTS-c to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.2,5,6
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for MOTS-c: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for MOTS-c are the records PeptideScanner has selected and published, not every registration or paper about MOTS-c. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists MOTS-c acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make MOTS-c an FDA-approved drug.↗↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Three selected human reports measured naturally occurring MOTS-c during exercise studies or in patients with coronary endothelial dysfunction. None of these reports tested administering MOTS-c to people.↗↗↗
What the reviewed sources report
Human studies associate endogenous MOTS-c with exercise or vascular measurements. Exercise interventions and biomarker associations do not demonstrate the efficacy or safety of administered MOTS-c.↗↗↗
What remains unresolved?
What evidence directly evaluates administered MOTS-c in humans, separately from exercise and endogenous biomarker studies?↗↗↗
How do assay methods, confounding and population differences affect observed associations?↗↗↗
Three selected human reports measured naturally occurring MOTS-c during exercise studies or in patients with coronary endothelial dysfunction. None of these reports tested administering MOTS-c to people.123
Bottom line from this bounded source set
Human studies associate endogenous MOTS-c with exercise or vascular measurements. Exercise interventions and biomarker associations do not demonstrate the efficacy or safety of administered MOTS-c.123
Reviewed study record
Acute exercise and circulating peptides
Design
Participants were randomized to endurance exercise, resistance exercise or a control group, with blood and muscle measurements.1
Population
Thirty participants were assigned to three groups of ten.1
Outcomes reported
Humanin increased after endurance exercise; MOTS-c showed a trend toward an increase.1
Limitations
The intervention was exercise, not MOTS-c administration. A trend is not a demonstrated clinical benefit, and the small study measured short-term biomarkers.1
Reviewed study record
Exercise in breast cancer survivors
Design
A secondary analysis of a randomized 16-week exercise-versus-usual-care study measured circulating MOTS-c.2
Population
The analysis included 25 Hispanic and 24 non-Hispanic White breast cancer survivors.2
Outcomes reported
MOTS-c increased in the non-Hispanic White subgroup and was associated with changes in metabolic measures; a comparable increase was not reported in the Hispanic subgroup.2
Limitations
Small subgroup analyses and baseline differences limit interpretation. Associations do not establish that MOTS-c caused the metabolic changes, and no peptide was administered.2
Reviewed study record
Coronary endothelial dysfunction
Design
An observational human comparison measured endogenous MOTS-c; separate experiments exposed rodent vessels to the peptide.3
Population
Forty patients undergoing angiography for recurrent angina were classified into two groups of twenty by endothelial function.3
Outcomes reported
Circulating MOTS-c was lower in patients with endothelial dysfunction and correlated with vascular function measures.3
Limitations
The human findings are associations. Exposure experiments used rodent tissues, so they do not establish a therapeutic effect or safety in people.3
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1152/japplphysiol.00706.2019. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1038/s41598-021-96419-z. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/j.ijcard.2017.12.001. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
The agency assessment found preclinical rather than treatment evidence
FDA’s July 2026 briefing did not identify studies administering the nominated MOTS-c substances to humans. It distinguished that absence from rodent and cell studies relevant to proposed metabolic and bone effects. FDA PDF pp. 25, 31 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
Bone-cell findings do not establish fracture prevention
The discussed bone experiments used cultured cells and rodent models. They do not demonstrate reduced fractures or a clinical osteoporosis benefit in people. FDA PDF pp. 24, 31 ↗
Mechanistic uncertainty limits extrapolation
FDA noted missing in-vivo dose-response evaluation and uncertainty about the molecular targets. It considered the clinical relevance of the preclinical findings unresolved. FDA PDF pp. 25, 31 ↗
The recommendation concerns the nominated substances
The briefing weighed against inclusion of MOTS-c free base and acetate on the 503A bulks list and described characterization gaps. This staff proposal is distinct from a final agency action or an assessment of every related analogue. FDA PDF pp. 1, 32 ↗
What remains to be checked
Check subsequent advisory records and any final FDA action separately from the staff briefing.
Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Human studies of endogenous MOTS-c biomarkers and studies administering the peptide, distinguished explicitly; animal or cell exposure cannot establish a human treatment effect.
255 retrieved · 3 included · 0 excluded · 252 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"MOTS-c"[Title/Abstract]
Regulator and trial-registry searches and non-indexed reports require separate reconciliation.
Full-text appraisal, study-family linkage and citation follow-up remain open.
Showing 25 of 255 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 34351816 — include: Selected endogenous biomarker study; no MOTS-c was administered to the human participants. Study families: MOTS-c-acute-exercise-2021.
PubMed 34413391 — include: Selected endogenous biomarker study; no MOTS-c was administered to the human participants. Study families: NCT01140282.
PubMed 29242099 — include: Selected endogenous biomarker study; no MOTS-c was administered to the human participants. Study families: MOTS-c-coronary-observational-2018.
PubMed 42633281 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42633878 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42734848 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42716952 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42640735 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42611943 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42576277 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42349896 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42321010 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42128272 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 41966639 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42650220 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42592019 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42142418 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 41933740 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42324588 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42243958 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42228044 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42153537 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42266945 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42278864 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
PubMed 42126770 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
8 retrieved · 0 included · 0 excluded · 8 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 8 of 8 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT04027712 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07438002 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03878706 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07638696 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06133946 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06500975 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07678073 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07505745 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of MOTS-c?
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists MOTS-c acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make MOTS-c an FDA-approved drug.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
43
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 43 dated records
We added a plain-language reader guide with cited answers, re-checked FDA’s MOTS-c briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists MOTS-c acetate. FDA has not issued a final 503A rule.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.
Selected records span June 15, 2020 to August 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained PubMed bibliographic metadata for PMID 42243958 at 2026-08-12T11:06:05.213Z. PubMed recorded a metadata revision date of 2026-08-12 and an Entrez history date of 2026-06-05. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42321010 at 2026-08-10T10:49:10.706Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-06-19. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42278864 at 2026-08-10T18:13:52.251Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-12. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42128272 at 2026-08-10T18:13:50.589Z. PubMed recorded a metadata revision date of 2026-07-16 and an Entrez history date of 2026-05-13. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41933740 at 2026-08-10T18:13:46.811Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-04-04. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41945630 at 2026-08-10T18:13:46.825Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-04-07. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41593376 at 2026-08-10T18:13:40.572Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-01-27. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41764620 at 2026-08-10T18:13:42.760Z. PubMed recorded a metadata revision date of 2026-07-10 and an Entrez history date of 2026-03-01. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41802484 at 2026-08-10T18:13:44.802Z. PubMed recorded a metadata revision date of 2026-07-10 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41811086 at 2026-08-10T18:13:44.817Z. PubMed recorded a metadata revision date of 2026-07-10 and an Entrez history date of 2026-03-11. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41706383 at 2026-08-10T18:13:42.683Z. PubMed recorded a metadata revision date of 2026-07-08 and an Entrez history date of 2026-02-18. PeptideScanner associated this retained record with the identity slug mots-c. These dates describe PubMed metadata history, not the article's original publication date.↗